Abstract
The pharmacokinetics of aztreonam were studied in 25 adult patients with hematological malignancies. Two groups of 9 patients each received aztreonam (1 or 2 g every 8 h) prophylactically, and 7 infected patients received a therapeutic regimen of aztreonam (1.5 g every 4 h). The mean peak serum concentration after a 1-g dose of aztreonam (given over 0.5 h on day 1) was 75.5 μg/ml; after a 2-g dose it was 177.2 μg/ml. The mean peak serum concentration after a 1.5-g dose of aztreonam (given over 2 h on day 1) was 68.5 μg/ml. The serum half-life ranged between 1.7 and 2.0 h for all regimens studied. The urinary concentration of the metabolite of aztreonam, SQ 26,992, increased during 1 week of administration of the drug; however, serum levels of the metabolite were barely detectable.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 455-461 |
| Number of pages | 7 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1984 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
Divisions
- Infectious Disease
Fingerprint
Dive into the research topics of 'Clinical pharmacokinetics of aztreonam in cancer patients'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS